# EDGAR Filing Document

**Accession Number:** 0001828316
**File Stem:** 0001828316-25-000031
**Filing Date:** 2025-6
**Character Count:** 15018
**Document Hash:** 3b14f5205baaf20aaa971151687250a2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001828316-25-000031.hdr.sgml**: 20250624

**ACCESSION NUMBER**: 0001828316-25-000031

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250624

**FILED AS OF DATE**: 20250624

**DATE AS OF CHANGE**: 20250624

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharming Group N.V.
- **CENTRAL INDEX KEY:** 0001828316
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39822
- **FILM NUMBER:** 251066572

**BUSINESS ADDRESS:**
- **STREET 1:** DARWINWEG 24
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CR
- **BUSINESS PHONE:** 31 (0)71 5247 400

**MAIL ADDRESS:**
- **STREET 1:** DARWINWEG 24
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CR

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pharming Group Group N.V.
- **DATE OF NAME CHANGE:** 20201014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June 2025**

**Commission File Number: 001-39822**

**Pharming Group N.V.**

(Exact Name of Registrant as Specified in Its Charter)

**Darwinweg 24**

**2333 CR Leiden**

**The Netherlands**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated June 24, 2025.

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Pharming Group N.V. | Pharming Group N.V. | Pharming Group N.V. |
| By: | /s/ Fabrice Chouraqui | /s/ Fabrice Chouraqui |
|  | Name: | Fabrice Chouraqui |
|  | Title: | CEO |

---

Date: June 24, 2025

------

![logo_pharmingxoriginala.jpg](logo_pharmingxoriginala.jpg)

**For media and investors only**

**Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Results enable clinical genetic testing labs to appropriately reclassify VUSs, accelerating the path to a definitive APDS diagnosis for many patients**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Findings reveal APDS may be more prevalent than previously estimated**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Webcast to take place on Monday, June 30, 2025, at 16:30 CEST / 10:30 EDT**

**Leiden, the Netherlands, June 24, 2025:** Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will host a webcast for investors and analysts featuring Joshua Milner, MD, an internationally renowned immunologist, to discuss the findings of a recent study published in the peer-reviewed journal *Cell*.

The study titled "Scalable generation and functional classification of genetic variants in inborn errors of immunity for improved clinical diagnosis and management" was led by Zachary Walsh, MD/PhD candidate, Dr. Milner and Benjamin Izar, MD, PhD of Columbia University. The publication details significant advances in diagnosing inborn errors of immunity, also known as primary immune disorders. The researchers' approach helps resolve a major limit to interpretation of genetic testing that often yields variants of uncertain significance (VUS) when evaluating such disorders, including activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

There are currently over 1,300 known U.S. patients with a VUS in the *PIK3CD* and *PIK3R1* genes implicated in APDS. The team at Columbia introduced more than 2,000 *PIK3CD/PIK3R1* variants, representing a portion of all potential variants, into human T-cell lines and assessed PI3Kδ pathway activity. These studies successfully confirmed known disease-causing APDS variants and, importantly, also identified over 100 new variants with evidence for PI3Kδ pathway hyperactivity. By analyzing very large datasets of patients who agreed to have their genetic testing linked to their medical records, the research team at Columbia concludes that the real prevalence of APDS may be higher than previously estimated.

During the call, Dr. Milner will provide insights into the study's methodology, key findings, implications, and next steps. Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts, extend the study to assess additional variants, and further investigate the clinical phenotype of APDS in the newly identified variants.

**Anurag Relan, MD, MPH, Chief Medical Officer of Pharming, commented:**

"This important study, recently published in Cell, is a key step towards providing answers to patients with a VUS in the PIK3CD or PIK3R1 genes. The study highlights the importance of increased genetic

------

![logo_pharmingxoriginala.jpg](logo_pharmingxoriginala.jpg)

screening and awareness to ensure timely diagnosis of APDS. We expect these data to enable clinical genetic testing laboratories to reclassify a portion of the VUSs, accelerating the path to a definitive APDS diagnosis for many patients. We look forward to additional near-term studies to facilitate the reclassification of the remaining VUSs and to further exploring the prevalence and phenotype of this rare disease."

**Dr Joshua Milner, MD, Director Division of Pediatric Allergy, Immunology and Rheumatology at Columbia University Irving Medical Center, commented:**

"This study offers a powerful new lens for interpreting VUSs and uncovering therapeutic insights in conditions like APDS. We hope these findings will support clinicians in making more informed decisions and ultimately lead to better outcomes for patients navigating rare immune disorders."

Note: This study was supported by a National Institutes of Health (NIH)/National Cancer Institute (NCI) grant and was in part supported through a sponsored research agreement with Pharming.

The webcast will take place on Monday, June 30, 2025, at 16:30 CEST / 10:30 EDT.

To participate, please register at https://edge.media-server.com/mmc/p/q6x83at2. Questions can be submitted in advance, via email to investor@pharming.com.

For more information and to access the full peer-reviewed study in *Cell*, please visit https://www.cell.com/cell/abstract/S0092-8674(25)00624-5.

**About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS)** 

APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as *PIK3CD* or *PIK3R1*, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation<sup>1,2,3</sup> APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.<sup>4,5</sup> Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.<sup>6</sup> As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.<sup>4-7</sup> A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide.

**About leniolisib**

Leniolisib is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved in the U.S., U.K., Australia and Israel as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a

------

![logo_pharmingxoriginala.jpg](logo_pharmingxoriginala.jpg)

favorable impact on the immune dysregulation and deficiency seen in these patients, and interim open label extension data has supported the safety and tolerability of long-term leniolisib administration.<sup>8,9</sup> Leniolisib is currently under regulatory review in the European Economic Area, Canada and several other countries for APDS, with plans to pursue regulatory approval in Japan. Leniolisib is also being evaluated in two Phase III clinical trials in children with APDS and in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS.

**About Pharming Group N.V.**

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

**Forward-looking Statements** 

*This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", ''anticipate'', ''believe'', ''could'', ''estimate'', ''expect'', ''goals'', ''intend'', ''may'', "milestones", ''objectives'', ''outlook'', ''plan'', ''probably'', ''project'', ''risks'', "schedule", ''seek'', ''should'', ''target'', ''will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.*

**References**

&nbsp;&nbsp;&nbsp;&nbsp;1.Lucas CL, et al. Nat Immunol. 2014;15(1):88-97.

&nbsp;&nbsp;&nbsp;&nbsp;2.Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.

------

![logo_greyxoriginalxa.jpg](logo_greyxoriginalxa.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;3.Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.

&nbsp;&nbsp;&nbsp;&nbsp;4.Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.

&nbsp;&nbsp;&nbsp;&nbsp;5.Maccari ME, et al. Front Immunol. 2018;9:543.

&nbsp;&nbsp;&nbsp;&nbsp;6.Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333.

&nbsp;&nbsp;&nbsp;&nbsp;7.Condliffe AM, Chandra A. Front Immunol. 2018;9:338.

&nbsp;&nbsp;&nbsp;&nbsp;8.Rao VK, et al Blood. 2023 Mar 2;141(9):971-983.

&nbsp;&nbsp;&nbsp;&nbsp;9.Rao VK, et al. J Allergy Clin Immunol 2024;153:265-74.

**For further public information, contact:**

*Pharming Group, Leiden, the Netherlands* 

Michael Levitan, VP Investor Relations & Corporate Communications

T: +1 (908) 705 1696

E: investor@pharming.com

*FTI Consulting, London, UK* 

Simon Conway/Alex Shaw/Amy Byrne

T: +44 203 727 1000

*LifeSpring Life Sciences Communication, Amsterdam, the Netherlands* 

Leon Melens

T: +31 6 53 81 64 27

E: pharming@lifespring.nl

*US PR*

Christina Skrivan

T: +1 (636) 352-7883

E: Christina.Skrivan@precisionaq.com

<br>